Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?

Ageing Research Reviews

Volumn 14, Issue 1, 2014, Pages 19-30

  Reeve, Amy ^a   Simcox, Eve ^a   Turnbull, Doug ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Ageing; Mitochondria; Neurodegeneration; Parkinson's disease

Indexed keywords

AGING; COMPLICATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; METABOLISM; MITOCHONDRION; NERVE CELL; PARKINSON DISEASE; PHYSIOLOGY; PROTEIN DENATURATION; SUBSTANTIA NIGRA;

AGING; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; NEURONS; PARKINSON DISEASE; PROTEIN DENATURATION; SUBSTANTIA NIGRA;

EID: 84894310713     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2014.01.004     Document Type: Review

References (142)

1. Abramov A.Y., Smulders-Srinivasan T.K., Kirby D.M., Acin-Perez R., Enriquez J.A., Lightowlers R.N., Duchen M.R., Turnbull D.M. Mechanism of neurodegeneration of neurons with mitochondrial DNA mutations. Brain 2010, 133(Pt 3):797-807.
2. Alemi M., Prigione A., Wong A., Schoenfeld R., DiMauro S., Hirano M., Taroni F., Cortopassi G. Mitochondrial DNA deletions inhibit proteasomal activity and stimulate an autophagic transcript. Free Radic. Biol. Med. 2007, 42(1):32-43.
3. Alvarez-Erviti L., Rodriguez-Oroz M.C., Cooper J.M., Caballero C., Ferrer I., Obeso J.A., Schapira A.H. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch. Neurol. 2010, 67(12):1464-1472.
4. Alvarez-Erviti L., Seow Y., Schapira A.H., Rodriguez-Oroz M.C., Obeso J.A., Cooper J.M. Influence of microRNA deregulation on chaperone-mediated autophagy and alpha-synuclein pathology in Parkinson's disease. Cell Death Dis. 2013, 4:e545.
5. Anglade P., Vyas S., Javoy-Agid F., Herrero M.T., Michel P.P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E.C., Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 1997, 12(1):25-31.
6. Anvret A., Westerlund M., Sydow O., Willows T., Lind C., Galter D., Belin A.C. Variations of the CAG trinucleotide repeat in DNA polymerase gamma (POLG1) is associated with Parkinson's disease in Sweden. Neurosci. Lett. 2010, 485(2):117-120.
7. Arnold B., Cassady S.J., VanLaar V.S., Berman S.B. Integrating multiple aspects of mitochondrial dynamics in neurons: age-related differences and dynamic changes in a chronic rotenone model. Neurobiol. Dis. 2011, 41(1):189-200.
8. Balafkan N., Tzoulis C., Muller B., Haugarvoll K., Tysnes O.B., Larsen J.P., Bindoff L.A. Number of CAG repeats in POLG1 and its association with Parkinson disease in the Norwegian population. Mitochondrion 2012, 12(6):640-643.
9. Baloyannis S.J., Costa V., Baloyannis I.S. Morphological alterations of the synapses in the locus coeruleus in Parkinson's disease. J. Neurol. Sci. 2006, 248(1-2):35-41.
10. Bedford L., Hay D., Devoy A., Paine S., Powe D.G., Seth R., Gray T., Topham I., Fone K., Rezvani N., Mee M., Soane T., Layfield R., Sheppard P.W., Ebendal T., Usoskin D., Lowe J., Mayer R.J. Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J. Neurosci. 2008, 28(33):8189-8198.
11. Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., Jaros E., Hersheson J.S., Betts J., Klopstock T., Taylor R.W., Turnbull D.M. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 2006, 38(5):515-517.
12. Bender A., Schwarzkopf R.M., McMillan A., Krishnan K.J., Rieder G., Neumann M., Elstner M., Turnbull D.M., Klopstock T. Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions. J. Neurol. 2008, 255(8):1231-1235.
13. Bendor J.T., Logan T.P., Edwards R.H. The function of alpha-synuclein. Neuron 2013, 79(6):1044-1066.
14. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3(12):1301-1306.
15. Betts-Henderson J., Jaros E., Krishnan K.J., Perry R.H., Reeve A.K., Schaefer A.M., Taylor R.W., Turnbull D.M. Alpha-synuclein pathology and Parkinsonism associated with POLG1 mutations and multiple mitochondrial DNA deletions. Neuropathol. Appl. Neurobiol. 2009, 35(1):120-124.
16. Bilgic B., Pfefferbaum A., Rohlfing T., Sullivan E.V., Adalsteinsson E. MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage 2012, 59(3):2625-2635.
17. Botella J.A., Bayersdorfer F., Schneuwly S. Superoxide dismutase overexpression protects dopaminergic neurons in a Drosophila model of Parkinson's disease. Neurobiol. Dis. 2008, 30(1):65-73.
18. Braak H., Braak E., Yilmazer D., Schultz C., de Vos R.A., Jansen E.N. Nigral and extranigral pathology in Parkinson's disease. J. Neural Transm. Suppl. 1995, 46:15-31.
19. Braak E., Sandmann-Keil D., Rub U., Gai W.P., de Vos R.A., Steur E.N., Arai K., Braak H. alpha-Synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol. 2001, 101(3):195-201.
20. Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318(1):121-134.
21. Breydo L., Wu J.W., Uversky V.N. alpha-Synuclein misfolding and Parkinson's disease. Biochim. Biophys. Acta 2012, 1822(2):261-285.
22. Buchman A.S., Shulman J.M., Nag S., Leurgans S.E., Arnold S.E., Morris M.C., Schneider J.A., Bennett D.A. Nigral pathology and Parkinsonian signs in elders without Parkinson disease. Ann. Neurol. 2012, 71(2):258-266.
23. Cali T., Ottolini D., Negro A., Brini M. alpha-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J. Biol. Chem. 2012, 287(22):17914-17929.
24. Campbell G.R., Ziabreva I., Reeve A.K., Krishnan K.J., Reynolds R., Howell O., Lassmann H., Turnbull D.M., Mahad D.J. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann. Neurol. 2011, 69(3):481-492.
25. Casali C., Bonifati V., Santorelli F.M., Casari G., Fortini D., Patrignani A., Fabbrini G., Carrozzo R., D'Amati G., Locuratolo N., Vanacore N., Damiano M., Pierallini A., Pierelli F., Amabile G.A., Meco G. Mitochondrial myopathy, Parkinsonism, and multiple mtDNA deletions in a Sephardic Jewish family. Neurology 2001, 56(6):802-805.
26. Chan C.S., Guzman J.N., Ilijic E., Mercer J.N., Rick C., Tkatch T., Meredith G.E., Surmeier D.J. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007, 447(7148):1081-1086.
27. Chen Q., Thorpe J., Keller J.N. Alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability. J. Biol. Chem. 2005, 280(34):30009-30017.
28. Cheng F., Vivacqua G., Yu S. The role of alpha-synuclein in neurotransmission and synaptic plasticity. J. Chem. Neuroanat. 2011, 42(4):242-248.
29. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75:333-366.
30. Clark I.E., Dodson M.W., Jiang C., Cao J.H., Huh J.R., Seol J.H., Yoo S.J., Hay B.A., Guo M. Drosophila pink1 is required for mitochondrial function and interacts genetically with Parkin. Nature 2006, 441(7097):1162-1166.
31. Corral-Debrinski M., Horton T., Lott M.T., Shoffner J.M., Beal M.F., Wallace D.C. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat. Genet. 1992, 2(4):324-329.
32. Daugherty A., Raz N. Age-related differences in iron content of subcortical nuclei observed in vivo: a meta-analysis. Neuroimage 2013, 70:113-121.
33. Davidzon G., Greene P., Mancuso M., Klos K.J., Ahlskog J.E., Hirano M., DiMauro S. Early-onset familial Parkinsonism due to POLG mutations. Ann. Neurol. 2006, 59(5):859-862.
34. de Brito O.M., Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 2008, 456(7222):605-610.
35. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5(6):525-535.
36. Del Tredici K., Braak H. Lewy pathology and neurodegeneration in premotor Parkinson's disease. Mov. Disord. 2012, 27(5):597-607.
37. Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 2008, 283(14):9089-9100.
38. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., Marsden C.D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 1989, 52(6):1830-1836.
39. Double K.L., Gerlach M., Schunemann V., Trautwein A.X., Zecca L., Gallorini M., Youdim M.B., Riederer P., Ben-Shachar D. Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem. Pharmacol. 2003, 66(3):489-494.
40. Double K.L., Dedov V.N., Fedorow H., Kettle E., Halliday G.M., Garner B., Brunk U.T. The comparative biology of neuromelanin and lipofuscin in the human brain. Cell. Mol. Life Sci. 2008, 65(11):1669-1682.
41. Dugger B.N., Murray M.E., Boeve B.F., Parisi J.E., Benarroch E.E., Ferman T.J., Dickson D.W. Neuropathological analysis of brainstem cholinergic and catecholaminergic nuclei in relation to rapid eye movement (REM) sleep behaviour disorder. Neuropathol. Appl. Neurobiol. 2012, 38(2):142-152.
42. Eerola J., Luoma P.T., Peuralinna T., Scholz S., Paisan-Ruiz C., Suomalainen A., Singleton A.B., Tienari P.J. POLG1 polyglutamine tract variants associated with Parkinson's disease. Neurosci. Lett. 2010, 477(1):1-5.
43. Ekstrand M.I., Terzioglu M., Galter D., Zhu S., Hofstetter C., Lindqvist E., Thams S., Bergstrand A., Hansson F.S., Trifunovic A., Hoffer B., Cullheim S., Mohammed A.H., Olson L., Larsson N.G. Progressive Parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl. Acad. Sci. U.S.A. 2007, 104(4):1325-1330.
44. Elson J.L., Samuels D.C., Turnbull D.M., Chinnery P.F. Random intracellular drift explains the clonal expansion of mitochondrial DNA mutations with age. Am. J. Hum. Genet. 2001, 68:802-806.
45. Elstner M., Muller S.K., Leidolt L., Laub C., Krieg L., Schlaudraff F., Liss B., Morris C., Turnbull D.M., Masliah E., Prokisch H., Klopstock T., Bender A. Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions. Mol. Brain 2011, 4:43.
46. Emmanouilidou E., Stefanis L., Vekrellis K. Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol. Aging 2010, 31(6):953-968.
47. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
48. Fedorow H., Halliday G.M., Rickert C.H., Gerlach M., Riederer P., Double K.L. Evidence for specific phases in the development of human neuromelanin. Neurobiol. Aging 2006, 27(3):506-512.
49. Friedman A., Galazka-Friedman J., Bauminger E.R. Iron as a trigger of neurodegeneration in Parkinson's disease. Hand. Clin. Neurol. 2007, 83:493-505.
50. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4(2):160-164.
51. Gasser T., Hardy J., Mizuno Y. Milestones in PD genetics. Mov. Disord. 2011, 26(6):1042-1048.
52. Gesi M., Soldani P., Giorgi F.S., Santinami A., Bonaccorsi I., Fornai F. The role of the locus coeruleus in the development of Parkinson's disease. Neurosci. Biobehav. Rev. 2000, 24(6):655-668.
53. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290(5493):985-989.
54. Gibb W.R., Lees A.J. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1991, 54(5):388-396.
55. Goldberg J.A., Guzman J.N., Estep C.M., Ilijic E., Kondapalli J., Sanchez-Padilla J., Surmeier D.J. Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease. Nat. Neurosci. 2012, 15(10):1414-1421.
56. Goo H.G., Jung M.K., Han S.S., Rhim H., Kang S. HtrA2/Omi deficiency causes damage and mutation of mitochondrial DNA. Biochim. Biophys. Acta 2013, 1833(8):1866-1875.
57. Greene J.C., Whitworth A.J., Kuo I., Andrews L.A., Feany M.B., Pallanck L.J. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila Parkin mutants. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(7):4078-4083.
58. Haacke E.M., Miao Y., Liu M., Habib C.A., Katkuri Y., Liu T., Yang Z., Lang Z., Hu J., Wu J. Correlation of putative iron content as represented by changes in R2* and phase with age in deep gray matter of healthy adults. J. Magn. Reson. Imaging 2010, 32(3):561-576.
59. Halliday G.M., Ophof A., Broe M., Jensen P.H., Kettle E., Fedorow H., Cartwright M.I., Griffiths F.M., Shepherd C.E., Double K.L. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 2005, 128(Pt 11):2654-2664.
60. Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., Yokoyama M., Mishima K., Saito I., Okano H., Mizushima N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441(7095):885-889.
61. Hirsch E.C., Graybiel A.M., Duyckaerts C., Javoy-Agid F. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc. Natl. Acad. Sci. U.S.A. 1987, 84(16):5976-5980.
62. Horvath R., Kley R.A., Lochmuller H., Vorgerd M. Parkinson syndrome, neuropathy, and myopathy caused by the mutation A8344G (MERRF) in tRNALys. Neurology 2007, 68(1):56-58.
63. Hudson G., Schaefer A.M., Taylor R.W., Tiangyou W., Gibson A., Venables G., Griffiths P., Burn D.J., Turnbull D.M., Chinnery P.F. Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and Parkinsonism. Arch. Neurol. 2007, 64(4):553-557.
64. Hudson G., Nalls M., Evans J.R., Breen D.P., Winder-Rhodes S., Morrison K.E., Morris H.R., Williams-Gray C.H., Barker R.A., Singleton A.B., Hardy J., Wood N.E., Burn D.J., Chinnery P.F. Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology 2013, 80(22):2042-2048.
65. Huerta C., Castro M.G., Coto E., Blazquez M., Ribacoba R., Guisasola L.M., Salvador C., Martinez C., Lahoz C.H., Alvarez V. Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population. J. Neurol. Sci. 2005, 236(1-2):49-54.
66. Itoh K., Weis S., Mehraein P., Muller-Hocker J. Cytochrome c oxidase defects of the human substantia nigra in normal aging. Neurobiol. Aging 1996, 17(6):843-848.
67. Jana N.R. Protein homeostasis and aging: role of ubiquitin protein ligases. Neurochem. Int. 2012, 60(5):443-447.
68. Kalia L.V., Kalia S.K., McLean P.J., Lozano A.M., Lang A.E. alpha-Synuclein oligomers and clinical implications for Parkinson disease. Ann. Neurol. 2013, 73(2):155-169.
69. Kastner A., Hirsch E.C., Lejeune O., Javoy-Agid F., Rascol O., Agid Y. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?. J. Neurochem. 1992, 59(3):1080-1089.
70. Khaliq Z.M., Bean B.P. Pacemaking in dopaminergic ventral tegmental area neurons: depolarizing drive from background and voltage-dependent sodium conductances. J. Neurosci. 2010, 30(21):7401-7413.
71. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J., Tanida I., Ueno T., Koike M., Uchiyama Y., Kominami E., Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441(7095):880-884.
72. Kraytsberg Y., Kudryavtseva E., McKee A.C., Geula C., Kowall N.W., Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet. 2006, 38(5):518-520.
73. Krishnan K.J., Reeve A.K., Samuels D.C., Chinnery P.F., Blackwood J.K., Taylor R.W., Wanrooij S., Spelbrink J.N., Lightowlers R.N., Turnbull D.M. What causes mitochondrial DNA deletions in human cells?. Nat. Genet. 2008, 40(3):275-279.
74. Krishnan K.J., Ratnaike T.E., De Gruyter H.L., Jaros E., Turnbull D.M. Mitochondrial DNA deletions cause the biochemical defect observed in Alzheimer's disease. Neurobiol. Aging 2012, 33(9):2210-2214.
75. Langston J.W., Ballard P.A. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N. Engl. J. Med. 1983, 309(5):310.
76. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219(4587):979-980.
77. Latsoudis H., Spanaki C., Chlouverakis G., Plaitakis A. Mitochondrial DNA polymorphisms and haplogroups in Parkinson's disease and control individuals with a similar genetic background. J. Hum. Genet. 2008, 53(4):349-356.
78. Lax N.Z., Hepplewhite P.D., Reeve A.K., Nesbitt V., McFarland R., Jaros E., Taylor R.W., Turnbull D.M. Cerebellar ataxia in patients with mitochondrial DNA disease: a molecular clinicopathological study. J. Neuropathol. Exp. Neurol. 2012, 71(2):148-161.
79. Lee S., Sterky F.H., Mourier A., Terzioglu M., Cullheim S., Olson L., Larsson N.G. Mitofusin 2 is necessary for striatal axonal projections of midbrain dopamine neurons. Hum. Mol. Genet. 2012, 21(22):4827-4835.
80. Leverenz J.B., Hamilton R., Tsuang D.W., Schantz A., Vavrek D., Larson E.B., Kukull W.A., Lopez O., Galasko D., Masliah E., Kaye J., Woltjer R., Clark C., Trojanowski J.Q., Montine T.J. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol. 2008, 18(2):220-224.
81. Li X.J., Li S. Proteasomal dysfunction in aging and Huntington disease. Neurobiol. Dis. 2011, 43(1):4-8.
82. Lowe J. Neuropathology of dementia with Lewy bodies. Handbook Clin. Neurol. 2008, 89:321-330.
83. Luoma P., Melberg A., Rinne J.O., Kaukonen J.A., Nupponen N.N., Chalmers R.M., Oldfors A., Rautakorpi I., Peltonen L., Majamaa K., Somer H., Suomalainen A. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 2004, 364(9437):875-882.
84. Ma S.Y., Ciliax B.J., Stebbins G., Jaffar S., Joyce J.N., Cochran E.J., Kordower J.H., Mash D.C., Levey A.I., Mufson E.J. Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. J. Comp. Neurol. 1999, 409(1):25-37.
85. Ma S.Y., Roytt M., Collan Y., Rinne J.O. Unbiased morphometrical measurements show loss of pigmented nigral neurones with ageing. Neuropathol. Appl. Neurobiol. 1999, 25(5):394-399.
86. Ma X., Liu H., Foyil S.R., Godar R.J., Weinheimer C.J., Hill J.A., Diwan A. Impaired autophagosome clearance contributes to cardiomyocyte death in ischemia/reperfusion injury. Circulation 2012, 125(25):3170-3181.
87. Maingay M., Romero-Ramos M., Carta M., Kirik D. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiol. Dis. 2006, 23(3):522-532.
88. Mancuso M., Filosto M., Oh S.J., DiMauro S. A novel polymerase gamma mutation in a family with ophthalmoplegia, neuropathy, and Parkinsonism. Arch. Neurol. 2004, 61(11):1777-1779.
89. Martin L.J., Pan Y., Price A.C., Sterling W., Copeland N.G., Jenkins N.A., Price D.L., Lee M.K. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 2006, 26(1):41-50.
90. McNaught K.S., Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 2001, 297(3):191-194.
91. McNaught K.S., Belizaire R., Isacson O., Jenner P., Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 2003, 179(1):38-46.
92. Mehta P., Mellick G.D., Rowe D.B., Halliday G.M., Jones M.M., Manwaring N., Vandebona H., Silburn P.A., Wang J.J., Mitchell P., Sue C.M. Mitochondrial DNA haplogroups J and K are not protective for Parkinson's disease in the Australian community. Mov. Disord. 2009, 24(2):290-292.
93. Miller K.E., Sheetz M.P. Axonal mitochondrial transport and potential are correlated. J. Cell Sci. 2004, 117(Pt 13):2791-2804.
94. Mortiboys H., Johansen K.K., Aasly J.O., Bandmann O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 2010, 75(22):2017-2020.
95. Murphy D.D., Rueter S.M., Trojanowski J.Q., Lee V.M. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 2000, 20(9):3214-3220.
96. Nakamura K., Nemani V.M., Azarbal F., Skibinski G., Levy J.M., Egami K., Munishkina L., Zhang J., Gardner B., Wakabayashi J., Sesaki H., Cheng Y., Finkbeiner S., Nussbaum R.L., Masliah E., Edwards R.H. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J. Biol. Chem. 2011, 286(23):20710-20726.
97. Nussbaum R.L., Ellis C.E. Alzheimer's disease and Parkinson's disease. N. Engl. J. Med. 2003, 348(14):1356-1364.
98. Ottolini D., Cali T., Negro A., Brini M. The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering. Hum. Mol. Genet. 2013, 22(11):2152-2168.
99. Pahapill P.A., Lozano A.M. The pedunculopontine nucleus and Parkinson's disease. Brain 2000, 123(Pt 9):1767-1783.
100. Pakkenberg B., Gundersen H.J. Neocortical neuron number in humans: effect of sex and age. J. Comp. Neurol. 1997, 384(2):312-320.
101. Parihar M.S., Parihar A., Fujita M., Hashimoto M., Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell. Mol. Life Sci. 2008, 65(7-8):1272-1284.
102. Parihar M.S., Parihar A., Fujita M., Hashimoto M., Ghafourifar P. Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. Int. J. Biochem. Cell Biol. 2009, 41(10):2015-2024.
103. Park J., Kim S.Y., Cha G.H., Lee S.B., Kim S., Chung J. Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. Gene 2005, 361:133-139.
104. Park J., Lee G., Chung J. The PINK1-Parkin pathway is involved in the regulation of mitochondrial remodeling process. Biochem. Biophys. Res. Commun. 2009, 378(3):518-523.
105. Perier C., Bender A., Garcia-Arumi E., Melia M.J., Bove J., Laub C., Klopstock T., Elstner M., Mounsey R.B., Teismann P., Prolla T., Andreu A.L., Vila M. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms. Brain 2013, 136(Pt 8):2369-2378.
106. Pickrell A.M., Pinto M., Hida A., Moraes C.T. Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurosci. 2011, 31(48):17649-17658.
107. Pissadaki E.K., Bolam J.P. The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease. Front. Comput. Neurosci. 2013, 7:13.
108. Pyle A., Foltynie T., Tiangyou W., Lambert C., Keers S.M., Allcock L.M., Davison J., Lewis S.J., Perry R.H., Barker R., Burn D.J., Chinnery P.F. Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Ann. Neurol. 2005, 57(4):564-567.
109. Reddy P.H., Shirendeb U.P. Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. Biochim. Biophys. Acta 2012, 1822(2):101-110.
110. Reddy P.H., Tripathi R., Troung Q., Tirumala K., Reddy T.P., Anekonda V., Shirendeb U.P., Calkins M.J., Reddy A.P., Mao P., Manczak M. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim. Biophys. Acta 2012, 1822(5):639-649.
111. Reeve A.K., Krishnan K.J., Taylor G., Elson J.L., Bender A., Taylor R.W., Morris C.M., Turnbull D.M. The low abundance of clonally expanded mitochondrial DNA point mutations in aged substantia nigra neurons. Aging Cell 2009, 8(4):496-498.
112. Reeve A.K., Park T.K., Jaros E., Campbell G.R., Lax N.Z., Hepplewhite P.D., Krishnan K.J., Elson J.L., Morris C.M., McKeith I.G., Turnbull D.M. Relationship between mitochondria and alpha-synuclein: a study of single substantia nigra neurons. Arch. Neurol. 2012, 69(3):385-393.
113. Reeve A., Meagher M., Lax N., Simcox E., Hepplewhite P., Jaros E., Turnbull D. The impact of pathogenic mitochondrial DNA mutations on substantia nigra neurons. J. Neurosci. 2013, 33(26):10790-10801.
114. Rubinsztein D.C., Marino G., Kroemer G. Autophagy and aging. Cell 2011, 146(5):682-695.
115. Rudow G., O'Brien R., Savonenko A.V., Resnick S.M., Zonderman A.B., Pletnikova O., Marsh L., Dawson T.M., Crain B.J., West M.J., Troncoso J.C. Morphometry of the human substantia nigra in ageing and Parkinson's disease. Acta Neuropathol. 2008, 115(4):461-470.
116. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1(8649):1269.
117. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 1990, 54(3):823-827.
118. Shima T., Sarna T., Swartz H.M., Stroppolo A., Gerbasi R., Zecca L. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free Radic. Biol. Med. 1997, 23(1):110-119.
119. Siciliano G., Mancuso M., Ceravolo R., Lombardi V., Iudice A., Bonuccelli U. Mitochondrial DNA rearrangements in young onset Parkinsonism: two case reports. J. Neurol. Neurosurg. Psychiatry 2001, 71(5):685-687.
120. Simon D.K., Pulst S.M., Sutton J.P., Browne S.E., Beal M.F., Johns D.R. Familial multisystem degeneration with Parkinsonism associated with the 11778 mitochondrial DNA mutation. Neurology 1999, 53(8):1787-1793.
121. Sofic E., Paulus W., Jellinger K., Riederer P., Youdim M.B. Selective increase of iron in substantia nigra zona compacta of Parkinsonian brains. J. Neurochem. 1991, 56(3):978-982.
122. Song L., Shan Y., Lloyd K.C., Cortopassi G.A. Mutant Twinkle increases dopaminergic neurodegeneration, mtDNA deletions and modulates Parkin expression. Hum. Mol. Genet. 2012, 21(23):5147-5158.
123. Soong N.W., Hinton D.R., Cortopassi G., Arnheim N. Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. Nat. Genet. 1992, 2(4):318-323.
124. Sterky F.H., Lee S., Wibom R., Olson L., Larsson N.G. From the cover: impaired mitochondrial transport and Parkin-independent degeneration of respiratory chain-deficient dopamine neurons in vivo. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(31):12937-12942.
125. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci. 2007, 30(5):244-250.
126. Surmeier D.J., Sulzer D. The pathology roadmap in Parkinson disease. Prion 2013, 7(1):85-91.
127. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., Sawa A.V.L.D, Dawson T.M., Ross C.A. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 2001, 10(9):919-926.
128. Taylor R.W., Barron M.J., Borthwick G.M., Gospel A., Chinnery P.F., Samuels D.C., Taylor G.A., Plusa S.M., Meddham S.J., Greaves L.C., Kirkwood B.L., Turnbull D.M. Mitochondrial mutations in human colonic crypt stem cells. J. Clin. Invest. 2003, 112(9):1351-1360.
129. Thomas K.J., McCoy M.K., Blackinton J., Beilina A., van der Brug M., Sandebring A., Miller D., Maric D., Cedazo-Minguez A., Cookson M.R. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum. Mol. Genet. 2010, 20(1):40-50.
130. Trevelyan A.J., Kirby D.M., Smulders-Srinivasan T.K., Nooteboom M., Acin-Perez R., Enriquez J.A., Whittington M.A., Lightowlers R.N., Turnbull D.M. Mitochondrial DNA mutations affect calcium handling in differentiated neurons. Brain 2010, 133(Pt 3):787-796.
131. Trifunovic A., Wredenberg A., Falkenberg M., Spelbrink J.N., Rovio A.T., Bruder C.E., Bohlooly Y.M., Gidlof S., Oldfors A., Wibom R., Tornell J., Jacobs H.T., Larsson N.G. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004, 429(6990):417-423.
132. Twig G., Elorza A., Molina A.J., Mohamed H., Wikstrom J.D., Walzer G., Stiles L., Haigh S.E., Katz S., Las G., Alroy J., Wu M., Py B.F., Yuan J., Deeney J.T., Corkey B.E., Shirihai O.S. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J. 2008, 27(2):433-446.
133. Uchikado H., Lin W.L., DeLucia M.W., Dickson D.W. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J. Neuropathol. Exp. Neurol. 2006, 65(7):685-697.
134. van der Walt J.M., Nicodemus K.K., Martin E.R., Scott W.K., Nance M.A., Watts R.L., Hubble J.P., Haines J.L., Koller W.C., Lyons K., Pahwa R., Stern M.B., Colcher A., Hiner B.C., Jankovic J., Ondo W.G., Allen F.H., Goetz C.G., Small G.W., Mastaglia F., Stajich J.M., McLaurin A.C., Middleton L.T., Scott B.L., Schmechel D.E., Pericak-Vance M.A., Vance J.M. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am. J. Hum. Genet. 2003, 72(4):804-811.
135. Verburg J., Hollenbeck P.J. Mitochondrial membrane potential in axons increases with local nerve growth factor or semaphorin signaling. J. Neurosci. 2008, 28(33):8306-8315.
136. Vincow E.S., Merrihew G., Thomas R.E., Shulman N.J., Beyer R.P., MacCoss M.J., Pallanck L.J. The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. Proc. Natl. Acad. Sci. U.S.A. 2013, 110(16):6400-6405.
137. Vogiatzi T., Xilouri M., Vekrellis K., Stefanis L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem. 2008, 283(35):23542-23556.
138. Wang X., Petrie T.G., Liu Y., Liu J., Fujioka H., Zhu X. Parkinson's disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction. J. Neurochem. 2012, 121(5):830-839.
139. Weihofen A., Thomas K.J., Ostaszewski B.L., Cookson M.R., Selkoe D.J. Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry 2009, 48(9):2045-2052.
140. Wood-Kaczmar A., Gandhi S., Wood N.W. Understanding the molecular causes of Parkinson's disease. Trends Mol. Med. 2006, 12(11):521-528.
141. Zecca L., Tampellini D., Gerlach M., Riederer P., Fariello R.G., Sulzer D. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol. Pathol. 2001, 54(6):414-418.
142. Zhou C., Zhong W., Zhou J., Sheng F., Fang Z., Wei Y., Chen Y., Deng X., Xia B., Lin J. Monitoring autophagic flux by an improved tandem fluorescent-tagged LC3 (mTagRFP-mWasabi-LC3) reveals that high-dose rapamycin impairs autophagic flux in cancer cells. Autophagy 2012, 8(8):1215-1226.